No Data
No Data
These four companies that are about to debut on the US stock market are worth focusing on. They may reverse the downturn in Biotech IPOs.
BioAge and Bicara hope to reverse the recent trend of obstacles in biotech companies' IPO in the US stock market; The binary nature of drug development has kept some investors away from the biotech industry.
Alumis to Participate in Upcoming September Investor Conferences
Express News | Samsara Biocapital LP Reports 6.9% Stake in Alumis Inc as of as of July 1 - SEC Filing
Express News | Cantor Fitzgerald Reiterates Overweight on Alumis
Alumis Analyst Ratings
Alumis Reports Q2 Results
No Data
No Data